Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(6 years from now) | |
US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(13 years from now) | |
US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(13 years from now) | |
US11254649 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Jun, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(3 years from now) | |
US8362002
(Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(4 years from now) | |
US7803839
(Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(7 years from now) | |
US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(11 years from now) | |
US11087354
(Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(11 years from now) | |
US10478400
(Pediatric) | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Dec, 2036
(13 years from now) | |
US10590102
(Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Dec, 2036
(13 years from now) | |
US11254649
(Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 10, 2022 |
New Indication (I) | Oct 28, 2025 |
M | Jul 28, 2025 |
Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9561217 | GENENTECH INC | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(1 year, 8 days ago) | |
US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(5 years from now) | |
US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(10 years from now) | |
US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(14 years from now) |
Drugs and Companies using PIRFENIDONE ingredient
Market Authorisation Date: 11 January, 2017
Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis; Dose escalation over 14 days for treatment of a fibrosis condition; Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis; Dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; Dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; Dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; Dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf; Administering pirfenidone while avoiding concomitant administration of a strong inducer of cyp1a2, including cigarette smoke, to avoid reduced pirfenidone efficacy; Discontinuing administration of fluvoxamine to avoid drug interactions with pirfenidone and then administering pirfenidone; Administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone; Discontinuing smoking to avoid reduced pirfenidone efficacy and then administering pirfenidone; Discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone; Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; Discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Discontinuing a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone; Administering pirfenidone while avoiding concomitant administration of a strong inducer of cyp1a2 to avoid reduced pirfenidone efficacy; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; Administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(10 years from now) | |
US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 7, 2027 |
New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 4, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 4, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(6 years from now) | |
US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(12 years from now) | |
US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(12 years from now) | |
US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
US11253515 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(15 years from now) | |
US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 15, 2026 |
New Chemical Entity Exclusivity (NCE) | Aug 15, 2024 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(8 years from now) | |
US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(7 years from now) | |
US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(8 years from now) | |
US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(14 years from now) | |
US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Oct 16, 2022 |
New Chemical Entity Exclusivity (NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: October, 2022
Market Authorisation Date: 24 October, 2018
Treatment: Method for post-exposure prophylaxis of influenza; Method for treating influenza
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic